Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL‐cholesterol levels: a 12‐week randomized trial
Key result
Micronized fenofibrate significantly increased HDL-C levels by 13.3% from baseline compared with 5.3% for atorvastatin over 12 weeks (P=0.0003).
Why the study?
Does micronized fenofibrate improve HDL-C levels compared to atorvastatin in nondiabetic dyslipidaemic patients with low HDL-C?
Population
181 randomized (165 analyzed) nondiabetic patients with low HDL-C (women <46 mg/dL, men <43 mg/dL)
Comparison
Micronized fenofibrate 200 mg/day for 12 weeks vs Atorvastatin 10 mg/day for 12 weeks
Design
RCT, randomized, open-label
Follow-up
12 weeks
Authors
Discussion
Loading...
Member takes
Implication
Fenofibrate raises HDL-C more effectively than atorvastatin in low-HDL dyslipidemia; extends RCT evidence on fibrate-statin lipid differences.
Study Design
Type
RCT (n=181)
Blinding
open-label
Randomization
randomized
Multicenter
Yes
Structured PICO
Does micronized fenofibrate improve HDL-C levels compared to atorvastatin in nondiabetic dyslipidaemic patients with low HDL-C?
P
Population
181 nondiabetic dyslipidaemic patients with low HDL-cholesterol levels followed for 12 weeks.
I
Intervention
Micronized fenofibrate 200 mg/day for 12 weeks
C
Comparator
Atorvastatin 10 mg/day for 12 weeks
O
Outcome
Percent change in HDL-C levels at 12 weekssurrogate
Main Result
Absolute Event Rate: 13.3% vs 5.3%
p-value: p=0.0003
Micronized fenofibrate is more effective than low-dose atorvastatin at raising HDL-C levels in nondiabetic dyslipidemic patients.
Cite This Study
Després et al. (2002) conducted an RCT in Dyslipidaemia with low HDL-cholesterol (n=181). Micronized fenofibrate vs. Atorvastatin (10 mg/day) was evaluated on Percent change in HDL-C levels (p=0.0003). Micronized fenofibrate significantly increased HDL-C levels by 13.3% from baseline compared with 5.3% for atorvastatin over 12 weeks (P=0.0003).